

RPW/1625



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s)	Iwao Ojima	Examiner:	Unassigned
Serial No.:	10/577,573	Group Art Unit:	Unassigned
Confirmation No:	6749	Docket:	178-330 PCT/US
Filed:	April 27, 2006	Dated:	March 23, 2007
For:	Taxoid-Fatty Acid Conjugates and Pharmaceutical Compositions Thereof		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

I hereby certify this correspondence is being deposited  
with the United States Postal Service as first class mail,  
postpaid in an envelope, addressed to: Commissioner  
for Patents, P.O. Box 1450, Alexandria, Virginia  
22313-1450 on March 23, 2007

Signed: *Deana J. Beale*

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R.  
§1.56, Applicant submits herewith the following Information Disclosure Statement in  
accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

The references are listed on Applicant's Form PTO-1449, which is attached to this  
Information Disclosure Statement for the convenience of the Examiner. Applicant requests  
consideration of each of the documents listed on the attached Form PTO-1449, and that such  
consideration be indicated by initialing each citation thereon.

Copies of each of the non-patent publications are enclosed herewith for the  
convenience of the Examiner.

Applicant: Iwao Ojima  
Serial No.: 10/577,573  
Filed: April 27, 2006  
Page 2 of 2

The Shashoua, et al. reference (U.S. Patent No. 5,795,909) was listed in the International Search Report issued in the corresponding International Application. A copy of the International Search Report accompanies this IDS.

This Statement is being filed before the mailing of a first Office Action on the merits. Applicant believes that no fee for this submission is due. If, however, a fee is due for entry of this Information Disclosure Statement, the Office is authorized to charge Deposit Account No. 08-2461 for any such fee.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicant's attorney at the telephone number set forth below.


Respectfully submitted,



---

Linda D. Chin  
Registration No.: 58,205  
Attorney for Applicant(s)

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550  
LDC/dlg  
234900\_1

FORM PTO-100 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
178-330 PCT/USSERIAL NO.  
10/577,573INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Iwao OjimaCONFIRMATION NO.  
6749

(Use several sheets if necessary)

FILING DATE  
April 27, 2006GROUP  
Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	5,919,815	July 6, 1999	Bradley, et al.			
	6,080,877	June 27, 2000	Swindell et al.			
	5,795,909	August 18, 1998	Shashoua et al.			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Bradley, et al. "Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel" <i>Clinical Cancer Research</i> Vol. 7:3229-3238 (2001)
	2	Interview with Nigel Webb "Better Benefits, Fewer Risks", Pharmaceutical Executive May 2001.
	3	Ojima, et al. "Synthesis and Structure-Activity Relationships of New Second-Generation Taxoids," <i>Bioorg. Med. Chem. Lett.</i> , 9:3423-3428 (1999)
	4	Ojima, et al. "Synthesis and Structure-Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity against Drug-Resistant Cancer Cells," <i>J. Med. Chem.</i> 39:3889-3896 (1996).
	5	Vredenburg, et al. "Effects of Orally Active Taxanes on P-Glycoprotein Modulation and Colon and Breast Carcinoma Drug Resistance," <i>Journal of the National Cancer Institute</i> 93(16):1234-1245 (August 2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.